Post by
MrMugsy on Apr 23, 2021 12:00am
Forget the share price ... follow the bouncing H2S molecule
The game is presently in development - the share price will follow - really doesn't matter.
Let's journey through the fields of Alzheimer's and see what we've got.
---------------------------------
A very interesting development with Biogen and their new drug candidate Aducanumab ... less than a coin throw chance of getting FDA approval (but it still could). The drug binds to amyloid beta tangles and reduces them - relieves symptoms but (NOTE) it does not reverse it. Causes headaches and swelling on the brain (ARIA). We'll come back to Biogen later.
So ... what's available to ATE that is off-patent? Donepezil can slow the decline from Alzheimer's for about 6 months. Side-effects include muscle cramping and some urination/control issues. I think ATE takes a pass on that one.
Last but not least, we have two drugs in a class of acetylcholinesterase inhibitors - improves ability to think and remember - slows the loss of abilities. Galantamine has a stomach pain side-effect but it also comes with extreme tiredness. Let's pass on that one because we don't want the patient to be over-tired as it turns them into a bump on a log.
That leaves us with Rivastigmine, also in the class of acetylcholinesterase inhibitors. Side-effects include stomach pain and heartburn/indigestion. Just maybe Rivastigmine with H2S becomes the future at ATE. That's my guess.
It will be interesting to see how Biogen fairs with Aducanumab or they just might turn an eye towards ATE to see what we're up to. Hahaha ! Interesting !
Comment by
MrMugsy on Apr 23, 2021 12:22am
One last thought ... if we did go the route of Rivastigmine, It's very likely that H2S would reduce the dosing for the active drug and we'd in turn reduce the stomach pain and the heartburn/indigestion. Maybe taking the meds with food is all we'd need in the end. Fingers crossed it's that easy !